Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

BACKGROUND: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class inhibitor of ataxia telangiectasia and Rad3-related protein kinase (ATR). We assessed multiple ascending doses of berzosertib + gemcitabine ± cisplatin in patients with resistant/refractory advanced sol...

Descripción completa

Detalles Bibliográficos
Autores principales: Middleton, Mark R., Dean, Emma, Evans, Thomas R. J., Shapiro, Geoffrey I., Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368196/
https://www.ncbi.nlm.nih.gov/pubmed/34040175
http://dx.doi.org/10.1038/s41416-021-01405-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368196/
https://www.ncbi.nlm.nih.gov/pubmed/34040175
http://dx.doi.org/10.1038/s41416-021-01405-x

Ejemplares similares